Rabia Ozden
Chief Tech/Sci/R&D Officer at ADVERUM BIOTECHNOLOGIES, INC.
Net worth: 169 598 $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Scott Whitcup | M | 64 | 7 years | |
| Laurent Fischer | M | 60 | 4 years | |
| Peter Soparkar | M | 53 | 5 years | |
| Clarence Machado | M | 60 | 7 years | |
| Reed Tuckson | M | 73 | 3 years | |
| Soo Hong | F | 52 | 2 years | |
| Anand Reddi | M | 42 | - | |
| Dawn Svoronos | F | 70 | 4 years | |
| Mark Lupher | M | 53 | 5 years | |
| C. Nicholson | M | 69 | 1 years | |
| John Rakow | M | 67 | 3 years | |
| Jim Scopa | M | 65 | 5 years | |
| Merilee Raines | F | 68 | 3 years | |
| Linda Rubinstein | F | 58 | 2 years | |
| Heikki Jouttijärvi | M | - | 4 years | |
| Karen-Leigh Edwards | M | - | 3 years | |
| Bill Tan | M | - | 3 years | |
| Sanjay Nayak | M | 54 | - | |
| Star Seyedkazemi | M | 50 | 2 years | |
| Pravin Dugel | M | 60 | - | |
| Romuald Corbau | M | 55 | - | |
| Dena House | F | - | 5 years | |
| Carla Fiankan | F | - | - | |
| R. Ramelmeier | M | 62 | 1 years | |
| Peter K. Kaiser | M | - | - | |
| Adrienne Graves | M | 69 | 1 years | |
| Szilárd Kiss | M | 49 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bruce Peacock | M | 72 | 8 years | |
| Antony Mattessich | M | 57 | 7 years | |
| William A. Sullivan | M | 52 | 4 years | |
| David Fellows | M | 67 | 4 years | |
| Chris Hollowood | M | 50 | 6 years | |
| Paula Cobb | F | 51 | 1 years | |
| Bryan Yoon | M | 46 | 2 years | |
| Gregory Robinson | M | 65 | 5 years | |
| Senthil Sundaram | M | 46 | 2 years | |
| Sona Saira Ramasastry | F | 48 | 2 years | |
| James McArthur | M | 62 | 3 years | |
| Rupert D’Souza | M | 65 | 1 years | |
| Anne VanLent | F | 76 | 6 years | |
| Lawrence E. Bullock | M | 67 | 3 years | |
| Arnold Lewis Oronsky | M | 83 | 14 years | |
| David Lubner | M | 60 | 2 years | |
| David Mott | M | 58 | 4 years | |
| Heather Elizabeth Preston | M | 58 | 2 years | |
| David Guyer | M | 64 | 3 years | |
| Vicki Sato | M | 75 | 2 years | |
| Chad Brines | M | - | 4 years | |
| Patricia Kitchen | F | 46 | 2 years | |
| Nancy E. Pecota | F | 64 | - | |
| Masa Tanaka | M | - |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 3 years |
| Sachiyo Minegishi | F | 46 | - | |
| Brigit Riley | M | 46 | 3 years | |
| Jon Williams | M | - | 1 years | |
| Jim Wang | M | - | 2 years | |
| Shawn Stetson | M | 47 | - | |
| Tu Yen Ong | M | 49 | 2 years | |
| Alan K. Smith | M | 68 | 1 years | |
| Trevor Anthony Mill | M | 53 | 1 years | |
| Steven John Green | M | 47 | 1 years | |
| Ellery Mangas | M | - | 5 years | |
| Michael H. Goldstein | M | 57 | 1 years | |
| Andrew Ashe | M | 57 | 1 years | |
| Robert Takeuchi | M | 67 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 3 years |
| Richard Beckman | M | 65 | 1 years | |
| Smadar Shakked Samira | F | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 14 years |
| Mark de Rosch | M | 61 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 54 | 80.60% |
| United Kingdom | 15 | 22.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rabia Ozden
- Personal Network